David Smoller Ph.D

David Smoller Ph.D General Information

Biography

Dr. David Smoller serves as a General Partner at Cultivation Capital. He serves as Executive-in-Residence & Investment Committee Member at BioGenerator Ventures. He serves as Board Member and Scientific Advisory Board at Immunophotonics. He serves as a Board Member and Advisor at Cofactor Genomics. He serves as a Board Member at Maximum Fidelity Surgical Simulation. He is a Co-Founder & serves as a Board Member at Panome Bio. He served as a Board Member at Solis Agrosciences and Kypha. He serves as an Executive Advisor at Thompson Street Capital Partners. He serves as an Entrepreneur In Residence & Investment Committee Member at BioGenerator. He served as a Board Member at Nanopore Diagnostics and Adarza BioSystems. Previously he served as Chief Business Officer & Board Member at Horizon Discovery. Prior to joining Horizon Discovery as its Chief Business officer. He was CEO of Sage Labs. Sage Labs was a life science company developing genetically modified Rodents using gene-editing technologies. Sage was acquired in 2014 by Horizon Discovery. Previous to SAGE Labs, he was Chief Scientific Officer for Sigma Aldrich. He joined Sigma-Aldrich in June 2004 as Vice President of R&D, a role in which he helped to expand Sigma-Aldrich's leadership position through the development of new and innovative products for Life Science and High Technology research. In October of 2005, he expanded his role from R&D to operations, heading up both R&D and operations for the Research Biotech Business Unit of Sigma-Aldrich. In July 2007, he was then promoted to President of the Research Biotech Business Unit within Sigma Life Science to drive the implementation of a number of commercial initiatives in Functional Genomics, Proteomics, Regenerative Medicine, Cell Biology, and Animal Models and services areas. Prior to joining Sigma-Aldrich, he was CEO and President of ProteoPlex, Inc., a seed-stage spinout focusing on functional genomics. He founded ProteoPlex, Inc. in 2001 and led the St. Louis-based company through its product development and final acquisition by EMD Biosciences (Merck KGaA). In 1992, he founded Genome Systems, Inc. in St. Louis, which provided the scientific community with access to genome project-related technologies. He stayed at the helm of the organization during its acquisition in 1996 by the Incyte Corporation, based in Palo Alto, California, and was promoted to Senior Vice President and leader of the organization's St. Louis operations, where he grew the staff to more than 250 people. During his tenure at Incyte, his responsibilities expanded and included the management of the $150 million Genomic Business Unit. This responsibility included overseeing the management of 700 hundred employees, as well as managing the strategic planning, product marketing, and research and development strategy of the unit. He earned a Ph.D. from Emory University and a BS in Biology from Emory University. He serves as Executive Chairman at BacterioScan.